--- title: "Neogen | 8-K: FY2026 Revenue Beats Estimate at USD 922.3 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294351142.md" datetime: "2026-07-30T11:05:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294351142.md) - [en](https://longbridge.com/en/news/294351142.md) - [zh-HK](https://longbridge.com/zh-HK/news/294351142.md) generator: "portal-rs" --- # Neogen | 8-K: FY2026 Revenue Beats Estimate at USD 922.3 M Revenue: As of FY2026, the actual value is USD 922.3 M, beating the estimate of USD 857.45 M. ### Financial Performance for Q4 FY26 and Full FY26 #### Segment Revenue - **Food Safety Segment**: Revenue for the fourth quarter was $166.8 million, an increase of 3.1% year-over-year, with Core Food Safety revenue growing 5.8%. Key contributors included Indicator Testing and Culture Media, up 9.5% to $86.8 million, and Bacterial and General Sanitation, which grew 9.9% to $46.7 million. Natural Toxins & Allergens revenue increased 3.8% to $19.2 million, and Food Safety Genomics Services grew 4.8% to $6.6 million. Revenue from Rodent Control, Insect Control & Disinfectants in the Food Safety segment decreased -65.5% to $3.9 million. - **Animal Safety Segment**: Revenue for the fourth quarter was $58.5 million, a decrease of -8.2% year-over-year, though Core Animal Safety revenue increased 0.5%. Animal Safety revenue sequentially increased over 7% due to the resolution of supply challenges. Life Sciences revenue grew 12.5% to $1.8 million, and Animal Safety Genomics Services increased 4.2% to $17.2 million. Veterinary Instruments & Disposables revenue decreased -1.9% to $15.8 million, while Animal Care & Other revenue decreased -12.5% to $7.0 million. Revenue from Rodent Control, Insect Control & Disinfectants in the Animal Safety segment decreased -22.3% to $16.7 million. #### Geographic Revenue Domestic revenue in the fourth quarter was $110.3 million, and international revenue was $115.0 million. Neogen Corporation experienced double-digit growth in Latin America and Food Safety growth across all global geographies in the quarter. #### Net Loss and Adjusted Net Income Neogen Corporation reported a net loss of - $11.3 million for the fourth quarter of fiscal year 2026, compared to a net loss of - $612.2 million in the prior-year period. Adjusted Net Income for the fourth quarter was $18.7 million, an increase from $11.3 million in the prior-year period. For the full fiscal year 2026, the net loss was - $7.9 million, compared to - $1,092.0 million in the previous fiscal year. Adjusted Net Income for the full fiscal year was $70.2 million, compared to $70.9 million in the prior year. #### Gross Profit and Gross Margin Gross profit for the fourth quarter was $107.8 million, up from $92.9 million in the same quarter last year, resulting in a gross margin of 47.8%, compared to 41.2% in Q4 FY25. Adjusted gross margin was 49.7% for the fourth quarter, up from 46.4% in the prior year. For the full fiscal year, gross profit was $408.5 million, down from $421.4 million in FY25, with a gross margin of 46.9% compared to 47.1% in FY25. #### Operating Income (Loss) and Operating Margin Operating income for the fourth quarter was $3.1 million, a significant improvement from an operating loss of - $611.2 million in Q4 FY25, resulting in an operating margin of 1.4% compared to -271.0% in Q4 FY25. Adjusted operating income for the fourth quarter was $39.1 million, up from $35.0 million in the prior-year period. For the full fiscal year, operating loss was - $21.6 million, compared to - $1,061.0 million in FY25, with an operating margin of -2.5% compared to -118.6% in FY25. Adjusted operating income for the full fiscal year was $153.9 million, down from $161.1 million in FY25. #### Adjusted EBITDA and Adjusted EBITDA Margin Fourth-quarter Adjusted EBITDA was $45.4 million, representing an Adjusted EBITDA Margin of 20.2%, compared to $40.6 million and an Adjusted EBITDA margin of 18.0% in the prior-year period. For the full fiscal year, Adjusted EBITDA was $177.8 million, down from $184.2 million in FY25, with an Adjusted EBITDA margin of 20.4% compared to 20.6% in FY25. #### Cash Flow Cash flow from operations for the fourth quarter was $30.2 million, and free cash flow was $26.2 million. For the full fiscal year 2026, net cash provided by operating activities was $83.2 million, and free cash flow was $31.9 million. #### Net Debt As of May 31, 2026, total debt was $793.7 million, and cash and cash equivalents were $185.5 million, resulting in net debt of $608.2 million. #### Operational Metrics and Unique Indicators Neogen Corporation is on track to manufacture sellable Petrifilm® product and begin its multi-quarter manufacturing transition to its Lansing site in November 2026, with the first fully validated single kit unit (SKU) expected by the end of August 2026. The company is supporting efforts against New World Screwworm (NWS) expansion in the United States by providing expanded availability of specific products for fly management. Neogen is also working to complete the sale of its global Genomics business to Zoetis Inc. by the end of the first half of fiscal year 2027, with anticipated total proceeds of $160 million and net proceeds of approximately $140 million after taxes and closing costs, which will be primarily used for debt reduction. The company’s Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification. Neogen is launching a new global go-to-market strategy and enterprise-wide solutions-based selling model, realigning sales resources and implementing unified solutions-based selling standards. ### Outlook / Guidance Neogen Corporation projects fiscal year 2027 total revenue in the range of $880 million to $885 million and Adjusted EBITDA between $180 million and $182 million. This guidance includes an estimated $92 million of revenue and $13 million in Adjusted EBITDA from the Genomics division, with management planning to update guidance post-divestiture. For the first quarter of fiscal year 2027, total revenue is expected to be $207 million to $209 million, with Adjusted EBITDA of approximately $37 million. ### Related Stocks - [NEOG.US](https://longbridge.com/en/quote/NEOG.US.md) ## Related News & Research - [Neogen CEO Nassif Mikheal reports acquisition of 370 common shares worth $4,369.70](https://longbridge.com/en/news/295106714.md) - [Neogen Q4 revenue beats on food safety segment growth](https://longbridge.com/en/news/294358241.md) - [09:38 ETFrom Low Cost to High Trust: How China's Hotel Linen Supply Chain Is Changing Global Procurement](https://longbridge.com/en/news/296797082.md) - [Crude Prices Supported as Strait of Hormuz Remains Closed](https://longbridge.com/en/news/296249506.md) - [Sand Grove Capital lifts Irish Continental stake to 4.49% from 3.58%](https://longbridge.com/en/news/296742335.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**